JUNB and gastric cancer: The findings in this study highlight the potential of therapeutics targeting JUNB in oxaliplatin resistance and support further clinical development of combination therapy with oxaliplatin and MAPK inhibitors for the treatment of advanced oxaliplatin-resistant patients with GC.